Seer Q1 2026 revenue $2.8M (-34% YoY); reaffirms FY2026 guidance of $16M-$18M

Seer, Inc.

Revenue $2.8M, down 34% from $4.2M YoY, driven by depressed academic funding and competitive activity.
Net loss $16.8M vs $19.9M prior year; operating expenses down 20% to $18.2M.
Reaffirmed full year 2026 revenue guidance of $16M-$18M (3% growth at midpoint).
Ended Q1 with ~$220M cash and investments; repurchased ~1.5M shares in the quarter.
Appointed Anthony (Tony) Bazarko as CCO; secured collaboration with Precision Health Research, Singapore (10,000 samples).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Seer, Inc. reported the quarter ended March 31, 2026 results: revenue $2.8 million, net income $16.8 million. Guidance reaffirmed.

Period: the quarter ended March 31, 2026
Revenue: $2.8 million
Net income: $16.8 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended March 31, 2026. Recent Highlights • Achieved revenue of $2.8 million in the first quarter of 2026 • Achieved a doubling of independent publications year-over-year to 84 total, accelerating third-party validation of Seer’s platform • Secured a

View on SEC.gov

Browse all earnings releases →

Seer, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-221696

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.